ScienceOpen: research and publishing network

For Researchers

Search
Advanced search

13

views

    

0

recommends

0

shares

Record: found
Abstract: found
Article: not found

Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment.

Author(s): Katja Heinig, Kazuhiro Miya, Tomonori Kamei, Elena Guerini, Daniela Fraier, Li Yu, Surendra Bansal, Peter Morcos

Publication date: 2016-07-01

Journal: Bioanalysis

Publisher: Future Science, LTD

Keywords: alectinib, matrix effect, cross-validation, column switching, anaplastic lymphoma kinase, LC–MS/MS, Alecensa®, plasma, phospholipids, non-small-cell lung cancer

Read this article at

ScienceOpenPublisher PubMed

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Alectinib is a novel anaplastic lymphoma kinase (ALK) inhibitor for treatment of patients with ALK-positive non-small-cell lung cancer who have progressed on or are intolerant to crizotinib. To support clinical development, concentrations of alectinib and metabolite M4 were determined in plasma from patients and healthy subjects.

Related collections

Author and article information

Journal

PubMed ID:: 27329641

DOI:: 10.4155/bio-2016-0068

Keywords: alectinib,matrix effect,cross-validation,column switching,anaplastic lymphoma kinase,LC–MS/MS,Alecensa®,plasma,phospholipids,non-small-cell lung cancer

Data availability:

Keywords: alectinib, matrix effect, cross-validation, column switching, anaplastic lymphoma kinase, LC–MS/MS, Alecensa®, plasma, phospholipids, non-small-cell lung cancer

Comments

Comment on this article

scite_

Similar content 41

See all similar

Cited by 6

See all cited by

- Version 1